Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESK-001 in Generalized Pustular Psoriasis and Erythrodermic Psoriasis
jRCT2071260031Recruiting
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of envudeucitinib in generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP), sponsored by Kaken Pharmaceutical Co., Ltd. Primary endpoint: CGI-I treatment response at Week 16. Started May 2026; status: recruiting.
02
Drugs
envudeucitinib
03
Conditions
generalized pustular psoriasis (GPP)erythrodermic psoriasis (EP)
Beyond the preview
Go deeper on jRCT2071260031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260031.